OKYO Pharma 将来の成長

Future 基準チェック /06

OKYO Pharmaは、70.4%と149.1%でそれぞれ年率70.4%で利益と収益が成長すると予測される一方、EPSはgrowで87.7%年率。

主要情報

70.4%

収益成長率

87.7%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	149.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Feb 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:OK11 - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2025	13	6	4	4	1
3/31/2024	N/A	-7	-6	-6	1
3/31/2023	N/A	-7	-6	-6	1
9/30/2022	N/A	-7	-5	-5	N/A
6/30/2022	N/A	-5	-4	-4	N/A
3/31/2022	N/A	-4	-4	-4	N/A
12/31/2021	N/A	-4	-3	-3	N/A
9/30/2021	N/A	-4	-3	-3	N/A
6/30/2021	N/A	-3	-2	-2	N/A
3/31/2021	N/A	-3	-1	-1	N/A
12/31/2020	N/A	-1	-1	-1	N/A
9/30/2020	N/A	0	-1	-1	N/A
6/30/2020	N/A	-1	-1	-1	N/A
3/31/2020	N/A	-1	-1	-1	N/A
12/31/2019	N/A	-3	N/A	N/A	N/A
9/30/2019	N/A	-4	-2	-2	N/A
6/30/2019	N/A	-4	-2	-2	N/A
3/31/2019	N/A	-4	-2	-2	N/A
12/31/2018	N/A	-3	N/A	N/A	N/A
9/30/2018	N/A	-2	-2	-2	N/A
6/30/2018	N/A	-11	-1	-1	N/A
3/31/2018	N/A	-20	-1	-1	N/A
12/31/2017	N/A	-20	-1	-1	N/A
9/30/2017	N/A	-19	-1	-1	N/A
6/30/2017	N/A	-10	-1	-1	N/A
3/31/2017	N/A	0	-1	-1	N/A
12/31/2016	N/A	0	0	0	N/A
9/30/2016	N/A	0	0	0	N/A
6/30/2016	N/A	-1	N/A	0	N/A
3/31/2016	N/A	-1	N/A	0	N/A
9/30/2015	N/A	-1	N/A	-1	N/A
6/30/2015	N/A	-1	N/A	-1	N/A
3/31/2015	N/A	-1	N/A	-1	N/A
12/31/2014	N/A	-4	N/A	-1	N/A
9/30/2014	N/A	-3	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A
12/31/2013	N/A	-8	N/A	-2	N/A
9/30/2013	N/A	-8	N/A	-2	N/A
6/30/2013	N/A	-5	N/A	-2	N/A
3/31/2013	N/A	-3	N/A	-3	N/A
12/31/2012	N/A	-3	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OK11今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OK11今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: OK11今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OK11来年は収益がないと予測されています。

高い収益成長: OK11来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OK11の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

OKYO Pharma 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘